← All companies

NWBO

Northwest Biotherapeutics, Inc.

NWBO OTC Pharmaceutical Preparations EDGAR ↗

$0.16

-0.01 -5.88%

Key statistics

from XBRL data in SEC filings

Market cap

$263M

Revenue (TTM)

$1.50M

Net income (TTM)

-$43.9M

EPS (TTM)

$-0.03

P/E ratio

—

Dividend yield

—

Free cash flow

-$46.3M

Cash

$1.79M

Total assets

$80.1M

Gross margin

—

52-week range

$0.14 – $0.37

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Took on a direct financial obligation Jul 31, 2026 8-K Regulation FD disclosure Jul 20, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 10-K Fiscal year ended 2025-12-31 Apr 15, 2026 8-K Completed an acquisition or disposition Apr 7, 2026 8-K Other events Jan 15, 2026 8-K Amended charter or bylaws; Shareholder vote results Jan 2, 2026 8-K Entered a material agreement; Took on a direct financial obligation Nov 20, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Entered a material agreement; Took on a direct financial obligation Oct 31, 2025 8-K Entered a material agreement Oct 30, 2025 8-K Other events Oct 24, 2025 8-K Other events Oct 14, 2025 10-Q Quarter ended 2025-06-30 Aug 14, 2025 10-Q Quarter ended 2025-03-31 May 15, 2025 10-K Fiscal year ended 2024-12-31 Mar 31, 2025 8-K Entered a material agreement; Took on a direct financial obligation Dec 26, 2024 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Entered a material agreement; Took on a direct financial obligation Nov 1, 2024 10-Q Quarter ended 2024-06-30 Aug 9, 2024 8-K Regulation FD disclosure Aug 2, 2024 8-K Shareholder vote results Jul 3, 2024 8-K Entered a material agreement Jun 4, 2024 10-Q Quarter ended 2024-03-31 May 10, 2024 8-K Entered a material agreement; Took on a direct financial obligation May 2, 2024 10-K/A Fiscal year ended 2023-12-31 Apr 29, 2024 8-K Director or officer change Mar 22, 2024 8-K Director or officer change Mar 14, 2024 10-K Fiscal year ended 2023-12-31 Mar 5, 2024 8-K Entered a material agreement; Took on a direct financial obligation Nov 16, 2023 10-Q Quarter ended 2023-09-30 Nov 9, 2023 10-Q Quarter ended 2023-06-30 Aug 9, 2023 10-Q Quarter ended 2023-03-31 May 10, 2023 8-K Entered a material agreement; Took on a direct financial obligation Mar 8, 2023 10-K Fiscal year ended 2022-12-31 Feb 28, 2023 8-K Amended charter or bylaws Jan 13, 2023 8-K Shareholder vote results Jan 6, 2023 10-Q Quarter ended 2022-09-30 Nov 9, 2022 10-Q Quarter ended 2022-06-30 Aug 9, 2022 8-K Modified rights of security holders; Amended charter or bylaws Jul 26, 2022